🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Today we announced new preclinical data presented at the 31st Annual Congress of ESGCT, highlighting our progress towards in vivo therapies for alpha-1 antitrypsin deficiency (AATD) and sickle cell disease (SCD). Read more here: tesseratherapeutics.com/news/tessera-t…

We are excited that our team will be presenting at this year's Society for Immunotherapy of Cancer Annual Meeting. If you are attending, please stop by our poster presentation to catch up on our latest advances towards novel T-cell based therapies. #SITC24

We're honored to be named a BioSpace 2025 Best Places to Work in Biopharma! #TeamTessera’s dedication and passion fuel our mission to cure disease by writing in the code of life. Join us in making a difference: lnkd.in/dzgPVnZh #BioSpace #BestPlacesToWork

#ICYMI, we are looking forward to attending #ASH24 to showcase our latest progress towards in vivo therapies for sickle cell disease and T-cell therapies. Learn more about our upcoming presentations here: tesseratherapeutics.com/news/tessera-t…

Grateful to give back! #TeamTessera volunteered with local nonprofits in #Boston for our 2nd annual Day of Service. Thanks to @BostonCares for connecting us with organizations making a positive impact. #community

🗓️Join us at #ASH24, where our team will be showcasing our preclinical data for our in vivo programs in sickle cell disease and T cell therapies. If you're attending, be sure to stop by our oral and poster presentations to learn more about our latest advancements.

Today we announced preclinical data presented at #ASH24, highlighting advances in our in vivo therapies for sickle cell disease (SCD) and T cell therapies. Read more here: tesseratherapeutics.com/news/tessera-t…

Today, we announced we have entered into an agreement with the Gates Foundation to jointly fund our in vivo program for sickle cell disease (SCD). Read more here: tesseratherapeutics.com/news/tessera-t…

In Flagship's annual letter, Founder & CEO Noubar Afeyan reflects on polyintelligence. From the outset at Tessera, we have harnessed polyintelligence to design and optimize our Gene Writersᵀᴹ, advancing innovative science into potentially transformative clinical applications.

Our CSO spoke with Cell&Gene about our in vivo efforts to develop a genetic medicine for sickle cell disease (SCD), key challenges ahead, the investment from the Gates Foundation, and how Gene Writers could reshape SCD treatment globally. 🔗 Read more: cellandgene.com/doc/tessera-th…

On #IDWGS2025 , we're passing the mic to #TeamTessera! Hear their passion, journeys & advice for the next generation of women innovators. Their leadership is shaping the future of genetic medicine—driving discovery, inspiring progress & making a lasting impact. 💡🔬

As #BlackHistoryMonth comes to a close, we honor the voices and contributions of the Black community. Shandrolyn Ezhan shares how this month deepens her connection to her heritage and purpose.

Our mission is to cure disease by writing in the code of life. Through our #GeneWriting platform, we strive to address major unmet medical needs and explore new possibilities for treating rare genetic diseases. Today and every day, we stand with the #RareDisease community.

Mentorship at Tessera is about more than pairing people—it’s about creating space to grow, challenge assumptions, and build trust across teams. We recently kicked off this year’s program with a Mentorship Mixer, celebrating the connections at the heart of it all. #TeamTessera

This #EarthDay, we’re celebrating the power of community and action with our Green Employee Resource Group. From seed swaps to cleanups and composting, we’re building a culture of sustainability—one choice at a time. Together, we’re learning and growing toward a greener future.

Join us at #ASGCT2025 as we showcase multiple new preclinical datasets from our in vivo programs. See our full line-up here: tesseratherapeutics.com/news/tessera-t…

At #ASGCT2025, our team will be highlighting the latest advancements in our in vivo programs from our Gene Writing and delivery platforms.  📍 Full details below. If you’re attending, we’d love to connect and share more about our progress—be sure to stop by.

Congrats to AV Eggimann on receiving the #ASGCT Catalyst Award! Her leadership in regulatory science has helped shape how cell and gene therapies reach patients. We're proud to have her guiding our work at Tessera as we advance a new class of genetic medicines. #GeneWriting

Today we announced preclinical data presented at the American Society of Gene & Cell Therapy 28th Annual Meeting, featuring advances across our in vivo programs and delivery platform.  Read more here: tesseratherapeutics.com/news/tessera-t…

Our Wisdom Circle series—led by TesseRA, our Research Associate community—sparks real talk with leaders about the many paths a biotech career can take. 🌱🔬 💡 Key takeaway: Careers aren’t linear. Growth comes from learning, evolving & embracing change.